Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR

Oncotarget

Volumn 6, Issue 13, 2015, Pages 11150-11161

  Wang, Yuan Liang ^a   Overstreet, Anne Marie ^a   Chen, Min Shan ^a   Wang, Jiang ^a   Zhao, Hua Jun ^a,c   Ho, Po Chun ^a   Smith, Molly ^a,b   Wang, Shao Chun ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

B catenin; Breast cancer; c ABL; EGFR; lncRNA

Indexed keywords

BETA CATENIN; HOX ANTISENSE INTERGENIC RNA; IMATINIB; LAPATINIB; LONG UNTRANSLATED RNA; LYMPHOID ENHANCER FACTOR 1; PROTEIN TCF4; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ABELSON KINASE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; HOTAIR LONG UNTRANSLATED RNA, HUMAN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GENE REPRESSION; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; PROMOTER REGION; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DRUG SCREENING; ENZYME IMMUNOASSAY; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-ABL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, LONG NONCODING; RNA, MESSENGER; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929648711     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3441     Document Type: Article

References (44)

1. Pal S.K, Childs B.H, Pegram M. Triple negative breast cancer:unmet medical needs. Breast Cancer Res Treat. 2011; 125:627-36.
2. Sergina N.V, Moasser M.M. The HER family and cancer:emerging molecular mechanisms and therapeutic targets. Trends in Molecular Medicine. 2007; 13:527-534.
3. Ciardiello F, Tortora G. EGFR Antagonists in Cancer Treatment. N Engl J Med. 2008; 358:1160-1174.
4. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol. 2009; 20:1913-27.
5. Hoadley K.A, Weigman V.J, Fan C, Sawyer L.R, He X, Troester M.A, Sartor C.I, Rieger-House T, Bernard P.S, Carey L.A, Perou C.M. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics. 2007; 8:258.
6. Nielsen T.O, Hsu F.D, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen L.A, Ragaz J, Gown A.M, Gilks C.B, van de Rijn M, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10:5367-74.
7. Corkery B, Crown J, Clynes M, O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol. 2009; 20:862-7.
8. Modi S, D'Andrea G, Norton L, Yao T.J, Caravelli J, Rosen P.P, Hudis C, Seidman A.D. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer. 2006; 7:270-7.
9. Finn R.S, Press M.F, Dering J, Arbushites M, Koehler M, Oliva C, Williams L.S, Di Leo A. Estrogen receptor progesterone receptor human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as firstline treatment in HER2-negative or unknown metastatic breast cancer. Journal of Clinical Oncology. 2009; 27:3908-3915.
10. Lin J, Arlinghaus R. Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene. 2008; 27:4385-4391.
11. Zhao H, Ho P.-C, Lo Y.-H, Espejo A, Bedford M.T, Hung M.-C, Wang S.-C. Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer. PLoS ONE. 2012; 7:e29416.
12. Srinivasan D, Plattner R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res. 2006; 66:5648-5655.
13. Srinivasan D, Sims J.T, Plattner R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene. 2008; 27:1095-105.
14. Sirvent A, Boureux A, Simon V, Leroy C, Roche S. The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells. Oncogene. 2007; 26:7313-23.
15. Zhao H, Lo Y.-H, Yu L, Wang S.-C. Overcoming resistance to fulvestrant (ICI182,780) by Downregulating the c-ABL Proto-Oncogene in breast cancer. Mol Carcinog. 2011; 50:383-389.
16. Zhao H, Ou-Yang F, Chen I.F, Hou M.F, Yuan S.S, Chang H.L, Lee Y.C, Plattner R, Waltz S.E, Ho S.M, Sims J, Wang S.C. Enhanced Resistance to Tamoxifen by the c-ABL Proto-oncogene in Breast Cancer. Neoplasia. 2010; 12:214-223.
17. Lo Y.H, Ho P.C, Zhao H, Wang S.C. Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016). Anticancer Res. 2011; 31:789-95.
18. Wapinski O, Chang H.Y. Long noncoding RNAs and human disease. Trends Cell Biol. 2011; 21:354-61.
19. Wang K, Chang H. Molecular Mechanisms of Long Noncoding RNAs. Molecular Cell. 2011; 43:904-914.
20. Rinn J.L, Kertesz M, Wang J.K, Squazzo S.L, Xu X, Brugmann S.A, Goodnough L.H, Helms J.A, Farnham P.J, Segal E, Chang H.Y. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007; 129:1311-23.
21. Gupta R.A, Shah N, Wang K.C, Kim J, Horlings H.M, Wong D.J, Tsai M.C, Hung T, Argani P, Rinn J.L, Wang Y, Brzoska P, Kong B, Li R, West R.B, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464:1071-6.
22. Amaral P.P, Clark M.B, Gascoigne D.K, Dinger M.E, Mattick J.S. lncRNAdb, a reference database for long noncoding RNAs. Nucleic Acids Research. 2011.
23. Mosimann C, Hausmann G, Basler K. b-catenin hits chromatin:regulation of Wnt target gene activation. Nat Rev Mol Cell Biol. 2009; 10:276-86.
24. Polakis P. The oncogenic activation of β-catenin. Current Opinion in Genetics & Development. 1999; 9:15-21.
25. Klein P.S, Melton D.A. A molecular mechanism for the effect of lithium on development. Proceedings of the National Academy of Sciences. 1996; 93:8455-8459.
26. Hedgepeth C.M, Conrad L.J, Zhang J, Huang H.-C, Lee V.M.Y, Klein P.S. Activation of the Wnt Signaling Pathway: A Molecular Mechanism for Lithium Action. Developmental Biology. 1997; 185:82-91.
27. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis A.P, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, et al. The beta-catenin/ TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002; 111:241-50.
28. Geyer F.C, Lacroix-Triki M, Savage K, Arnedos M, Lambros M.B, MacKay A, Natrajan R, Reis-Filho J.S. b-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol. 2011; 24:209-231.
29. Astsaturov I, Ratushny V, Sukhanova A, Einarson M.B, Bagnyukova T, Zhou Y, Devarajan K, Silverman J.S, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto R.E, Sharma C, Jablonski S.A, Serebriiskii I.G, et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci. Signal. 2010; 3:ra67.
30. Hu T, Li C. Convergence between Wnt-beta-catenin and EGFR signaling in cancer. Mol Cancer. 2010; 9:236.
31. Cross D.A, Alessi D.R, Cohen P, Andjelkovich M, Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995; 378:785-9.
32. He X. Unwinding a Path to Nuclear b-Catenin. Cell. 2006; 127:40-42.
33. Yang L, Lin C, Liu Z.-R. P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing axin from b-Catenin. Cell. 2006; 127:139-155.
34. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K, Lu Z. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature. 2011; 480:118-22.
35. Rappa G, Anzanello F, Lorico A. Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells. Cancer Chemotherapy and Pharmacology. 2011; 67:919-926.
36. Panjarian S, Iacob R.E, Chen S, Engen J.R, Smithgall T.E. Structure and Dynamic Regulation of Abl Kinases. Journal of Biological Chemistry. 2013; 288:5443-5450.
37. Meltser V, Ben-Yehoyada M, Shaul Y. c-Abl tyrosine kinase in the DNA damage response: cell death and more. Cell Death Differ. 2011; 18:2-4.
38. Suzuki J, Sukezane T, Akagi T, Georgescu M.M, Ohtani M, Inoue H, Jat P.S, Goff S.P, Hanafusa H, Shishido T. Loss of c-abl facilitates anchorage-independent growth of p53- and RB- deficient primary mouse embryonic fibroblasts. Oncogene. 2004; 23:8527-34.
39. Chisholm K.M, Wan Y, Li R, Montgomery K.D, Chang H.Y, West R.B. Detection of Long Non-Coding RNA in Archival Tissue: Correlation with Polycomb Protein Expression in Primary and Metastatic Breast Carcinoma. PLoS ONE. 2012; 7:e47998.
40. Zheng G.X.Y, Do B.T, Webster D.E, Khavari P.A, Chang H.Y. Dicer-microRNA-Myc circuit promotes transcription of hundreds of long noncoding RNAs. Nat Struct Mol Biol. 2014; 21:585-590.
41. Trimarchi T, Bilal E, Ntziachristos P, Fabbri G, Dalla-Favera R, Tsirigos A, Aifantis I. Genome-wide Mapping and Characterization of Notch-Regulated Long Noncoding RNAs in Acute Leukemia. Cell. 2014; 158:593-606.
42. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999; 18:1223-34.
43. Wang S.-C, Nakajima Y, Yu Y.-L, Xia W, Chen C.-T, Yang C.-C, McIntush E.W, Li L.-Y, Hawke D.H, Kobayashi R, Hung M.-C. Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol. 2006; 8:1359-1368.
44. Schmittgen T.D, Livak K.J. Analyzing real-time PCR data by the comparative CT method. Nat. Protocols. 2008; 3:1101-1108.